---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-010765"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:34:34.053108+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ENDRA files FDA De Novo for TAEUS liver system; Q2 loss $2.6M, cash $4.8M

## Summary
- Submitted De Novo request to FDA for TAEUS liver fat assessment system; clinical data showed 90% sensitivity and correlation r=0.78 vs MRI-PDFF.
- Q2 2023 net loss $2.6M ($0.43/share) vs $3.6M ($1.17) in Q2 2022; operating expenses fell to $3.0M from $3.6M.
- Cash and equivalents $4.8M at June 30; $4.7M net raised in May 2023 public offering to extend runway through key 2023 milestones.
- IP portfolio expanded to 64 issued patents globally; four new patents issued in Q2 (one US, three China).

## SEC filing metadata
- accession: 0001654954-23-010765
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495423010765/0001654954-23-010765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495423010765/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-010765
- JSON: https://secwatch.observer/filing/0001654954-23-010765.json
- Plain text: https://secwatch.observer/filing/0001654954-23-010765.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported the quarter ended June 30, 2023 results: net income Net loss in the second quarter of 2023 was $2.6 million, or $0.43 per share, EPS $0.43 per share.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss in the second quarter of 2023 was $2.6 million, or $0.43 per share
  - EPS: $0.43 per share
  - Result: reported results
  source text: On August 14, 2023, ENDRA Life Sciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495423010765/0001654954-23-010765-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.